4//SEC Filing
Sherman Jeffrey Scott 4
Accession 0001077183-24-000072
CIK 0001077183other
Filed
May 13, 8:00 PM ET
Accepted
May 14, 9:38 PM ET
Size
19.7 KB
Accession
0001077183-24-000072
Insider Transaction Report
Form 4
Sherman Jeffrey Scott
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-11+13,005→ 138,667 total - Tax Payment
Common Stock
2024-05-11$14.86/sh−3,167$47,062→ 135,500 total - Exercise/Conversion
Common Stock
2024-05-11+13,005→ 148,505 total - Exercise/Conversion
Restricted Stock Unit
2024-05-11−13,005→ 26,011 totalExercise: $0.00→ Common Stock (13,005 underlying)
Holdings
- 73,016
Stock Option (Right to Buy)
Exercise: $19.65Exp: 2030-05-11→ Common Stock (73,016 underlying) - 77,913
Stock Option (Right to Buy)
Exercise: $16.45Exp: 2034-02-23→ Common Stock (77,913 underlying) - 39,016
Performance Stock Unit
Exercise: $0.00From: 2026-05-11→ Common Stock (39,016 underlying) - 46,606
Restricted Stock Unit
Exercise: $0.00→ Common Stock (46,606 underlying) - 249,169
Stock Option (Right to Buy)
Exercise: $11.62Exp: 2029-12-05→ Common Stock (249,169 underlying) - 46,606
Performance Stock Unit
Exercise: $0.00From: 2027-02-23→ Common Stock (46,606 underlying)
Footnotes (10)
- [F1]Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
- [F10]On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
- [F2]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
- [F3]On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F4]Once vested, the shares of common stock are not subject to expiration.
- [F5]On December 5, 2022, Mr. Sherman was granted 249,169 stock options. These awards vest ratably over four years with the first tranche vesting on December 7, 2023.
- [F6]On May 11, 2023, Mr. Sherman was granted 73,016 stock options. These options vest ratably over the first three anniversary dates of the grant date.
- [F7]On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
- [F8]On February 23, 2024, Mr. Sherman was granted 77,913 stock options. These options vest ratably over the first three anniversary dates of the grant date.
- [F9]On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
Documents
Issuer
NEOGENOMICS INC
CIK 0001077183
Entity typeother
Related Parties
1- filerCIK 0001463145
Filing Metadata
- Form type
- 4
- Filed
- May 13, 8:00 PM ET
- Accepted
- May 14, 9:38 PM ET
- Size
- 19.7 KB